Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Ullrich

Showing results (1-10 of 130) with videos related to

Pageof 13
Sort By:
Oncology|November 8, 2002
Molecular targets in cancer therapy and their impact on cancer managementAxel Ullrich
The Journal of Biological Chemistry|November 19, 2004
The unique C-terminal tail of the mitogen-activated protein kinase ERK5 regulates its activation and nuclear shuttlingMarcus Buschbeck, Axel Ullrich
Nature Reviews. Cancer|May 13, 2008
Paul Ehrlich's magic bullet concept: 100 years of progressKlaus Strebhardt, Axel Ullrich
FEBS Letters|October 7, 2006
Endothelin-1 inhibits adipogenesis: role of phosphorylation of Akt and ERK1/2Indranil Bhattacharya, Axel Ullrich
The New England Journal of Medicine|December 8, 2006
Another look at imatinib mesylateKlaus Strebhardt, Axel Ullrich
International Journal of Cancer|October 25, 2011
PRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma-cell linesClaus Bender, Axel Ullrich
Biochemical and Biophysical Research Communications|May 14, 2013
NEK9 depletion induces catastrophic mitosis by impairment of mitotic checkpoint control and spindle dynamicsYasuyuki Kaneta, Axel Ullrich
Nature Reviews. Cancer|March 25, 2006
Targeting polo-like kinase 1 for cancer therapyKlaus Strebhardt, Axel Ullrich
Cellular Signalling|September 1, 2004
Protein tyrosine kinase Syk modulates EGFR signalling in human mammary epithelial cellsAnja Ruschel, Axel Ullrich
Molecular & Cellular Oncology|June 18, 2016
Membrane-proximal binding of STAT3 revealed by cancer-associated receptor variantsVijay K Ulaganathan, Axel Ullrich
Pageof 13

Showing results (1-10 of 130) with videos related to

Sort By:
Pageof 13
Oncology|November 8, 2002
Molecular targets in cancer therapy and their impact on cancer managementAxel Ullrich
The Journal of Biological Chemistry|November 19, 2004
The unique C-terminal tail of the mitogen-activated protein kinase ERK5 regulates its activation and nuclear shuttlingMarcus Buschbeck, Axel Ullrich
Nature Reviews. Cancer|May 13, 2008
Paul Ehrlich's magic bullet concept: 100 years of progressKlaus Strebhardt, Axel Ullrich
FEBS Letters|October 7, 2006
Endothelin-1 inhibits adipogenesis: role of phosphorylation of Akt and ERK1/2Indranil Bhattacharya, Axel Ullrich
The New England Journal of Medicine|December 8, 2006
Another look at imatinib mesylateKlaus Strebhardt, Axel Ullrich
International Journal of Cancer|October 25, 2011
PRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma-cell linesClaus Bender, Axel Ullrich
Biochemical and Biophysical Research Communications|May 14, 2013
NEK9 depletion induces catastrophic mitosis by impairment of mitotic checkpoint control and spindle dynamicsYasuyuki Kaneta, Axel Ullrich
Nature Reviews. Cancer|March 25, 2006
Targeting polo-like kinase 1 for cancer therapyKlaus Strebhardt, Axel Ullrich
Cellular Signalling|September 1, 2004
Protein tyrosine kinase Syk modulates EGFR signalling in human mammary epithelial cellsAnja Ruschel, Axel Ullrich
Molecular & Cellular Oncology|June 18, 2016
Membrane-proximal binding of STAT3 revealed by cancer-associated receptor variantsVijay K Ulaganathan, Axel Ullrich
Pageof 13